Key Highlights

  • Citius Oncology stockholders elected three Class II directors at the annual meeting held on September 29, 2026.
  • Dr. Eugene Holuka, Robert Smith and Carol Webb were elected to three-year terms running through 2029.
  • Wolf & Company, P.C. was ratified as auditor for the fiscal year ended September 30, 2026, with 73,533,649 votes for.
  • Each nominee drew about 67.8 million votes for, roughly 8.2 million withheld, and 6,255,142 broker non-votes.

Citius Oncology, Inc. (NASDAQ:CTOR) filed a Form 8-K reporting the results of its annual meeting of stockholders, held on September 29, 2026. The filing, made under Item 5.07 (Submission of Matters to a Vote of Security Holders), shows that holders elected three Class II directors to new terms and ratified Wolf & Company, P.C. as the company's independent registered public accounting firm.

The report is signed by Leonard Mazur, the company's Chairman and Chief Executive Officer, and lists the company's address as 11 Commerce Drive, Cranford, New Jersey.

The Director Election

The company has a classified board, meaning directors are divided into classes that stand for election in different years. At this meeting the Class II seats were on the ballot, and the filing states that the three nominees were elected to serve three-year terms running through 2029. The nominees were Dr. Eugene Holuka, Robert Smith and Carol Webb.

According to the filing, Dr. Holuka received 67,835,202 votes for and 8,267,153 votes withheld. Mr. Smith received 67,883,403 votes for and 8,218,952 withheld, and Ms. Webb received 67,895,374 votes for and 8,206,981 withheld. Each of the three also had 6,255,142 broker non-votes. A broker non-vote arises when a brokerage holds shares for a customer and lacks discretionary authority to vote on a particular item, such as a director election, without instructions from the owner. Those shares count toward establishing a quorum but are not counted as votes for or against the nominee.

The Auditor Ratification

Stockholders were also asked to ratify the appointment of Wolf & Company, P.C. as the company's independent registered public accounting firm for the fiscal year ended September 30, 2026. The filing reports 73,533,649 shares voted for the ratification and 8,809,478 voted against, with 14,370 abstentions. There were no broker non-votes on this item, which is typical because Brokers usually have discretion to vote on routine matters such as auditor ratification.

Ratification is generally an advisory step. The audit committee of a public company is responsible for selecting and overseeing the auditor, so a stockholder vote does not by itself change who performs the audit. Still, the result is disclosed so that investors can see how much support the appointment received.

Citius Oncology's Staggered Board and Audit Cycle

The fiscal year for which Wolf & Company, P.C. was ratified ended on September 30, 2026, the day after the meeting, so the audited financial statements for that year would be presented in the company's next Annual Report on Form 10-K. The three re-elected Class II directors are serving terms through 2029, and the other classes of the board will come up for election in later years under the staggered structure. Any change to board composition, auditor or governance arrangements before then would be reported in a new Form 8-K, most likely under Item 5.02 for director changes or Item 4.01 for a change in the auditor.